AR022105A1 - COMPOSICIoN QUE COMPRENDE UN POLíMERO TRIBLOQUE TIPO ABA O TIPO BAB, QUE TIENE PROPIEDADES DE GELACIoN TÉRMICA REVERSIBLE; DICHO POLíMERO TRIBLOQUE; COMPOSICIoN POLIMÉRICA ACUOSA BIODEGRADABLE DE LIBERACIoN DE DROGA QUE LO COMPRENDE Y MÉTODO PARA AUMENTAR LA SOLUBILIDAD DE UNA DROGA MEZCLÁNDOLA EN D - Google Patents

COMPOSICIoN QUE COMPRENDE UN POLíMERO TRIBLOQUE TIPO ABA O TIPO BAB, QUE TIENE PROPIEDADES DE GELACIoN TÉRMICA REVERSIBLE; DICHO POLíMERO TRIBLOQUE; COMPOSICIoN POLIMÉRICA ACUOSA BIODEGRADABLE DE LIBERACIoN DE DROGA QUE LO COMPRENDE Y MÉTODO PARA AUMENTAR LA SOLUBILIDAD DE UNA DROGA MEZCLÁNDOLA EN D

Info

Publication number
AR022105A1
AR022105A1 ARP990104952A ARP990104952A AR022105A1 AR 022105 A1 AR022105 A1 AR 022105A1 AR P990104952 A ARP990104952 A AR P990104952A AR P990104952 A ARP990104952 A AR P990104952A AR 022105 A1 AR022105 A1 AR 022105A1
Authority
AR
Argentina
Prior art keywords
composition
polymer
drug
triblock polymer
gel
Prior art date
Application number
ARP990104952A
Other languages
English (en)
Original Assignee
Macromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macromed Inc filed Critical Macromed Inc
Publication of AR022105A1 publication Critical patent/AR022105A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un polímero tribloque del tipo ABA o BAB soluble en agua, biodegradable que está formado por una cantidad mayor de un bloque polímerico A hidrofobicoconstituido por un poliéster biodegradable y una cantidad menor de un bloque polimérico Bhidrofílico de polietielenglicol (PEG), polímero tribloque que tieneun peso molecular promedio total de entre aproximadamente 2000 y 4990 y que posee propiedades de gelificacion térmica reversible. Concentraciones efectivas delpolímero tribloque yde una droga pueden estar contenidas uniformemente en una fase acuosa para formar una composicion de liberacion de droga. A temperaturaspor debajo de la temperatura de gelificacion del polímero tribloque la composicion es un líquido, y a latemperatura de gelific acion o atemperaturas por encimade la misma la composicion es un gel o semisolido. La composicion puede ser administrada a un animal de sangre caliente en la forma de un líquido por medio deadministracion parenteral, ocular,topica, inhalacion, trans dermal, vaginal, transuretal, rectal, nasal, oral, pulmonar o aural y es un gel a la temperaturacorporal. La composicion también puede ser administrada como un gel. La droga es liberada a una velocidad controlada del gelque se biodegrada en producto s notoxicos. La velocidad de liberacion de la droga puede ser ajustada por la variacion de varios parámetros tales como el contenido del componente hidrofobico/hidrofílico, la concentracion polimérica, el peso moleculary la polidispersidad del polím ero tribloque. Debido a que el polímero tribloque es anfifílico,funciona para aumentar la solubilidad y/o estabilidad de drogas en la composicion.
ARP990104952A 1998-10-01 1999-09-30 COMPOSICIoN QUE COMPRENDE UN POLíMERO TRIBLOQUE TIPO ABA O TIPO BAB, QUE TIENE PROPIEDADES DE GELACIoN TÉRMICA REVERSIBLE; DICHO POLíMERO TRIBLOQUE; COMPOSICIoN POLIMÉRICA ACUOSA BIODEGRADABLE DE LIBERACIoN DE DROGA QUE LO COMPRENDE Y MÉTODO PARA AUMENTAR LA SOLUBILIDAD DE UNA DROGA MEZCLÁNDOLA EN D AR022105A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/164,865 US6117949A (en) 1998-10-01 1998-10-01 Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties

Publications (1)

Publication Number Publication Date
AR022105A1 true AR022105A1 (es) 2002-09-04

Family

ID=22596415

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104952A AR022105A1 (es) 1998-10-01 1999-09-30 COMPOSICIoN QUE COMPRENDE UN POLíMERO TRIBLOQUE TIPO ABA O TIPO BAB, QUE TIENE PROPIEDADES DE GELACIoN TÉRMICA REVERSIBLE; DICHO POLíMERO TRIBLOQUE; COMPOSICIoN POLIMÉRICA ACUOSA BIODEGRADABLE DE LIBERACIoN DE DROGA QUE LO COMPRENDE Y MÉTODO PARA AUMENTAR LA SOLUBILIDAD DE UNA DROGA MEZCLÁNDOLA EN D

Country Status (5)

Country Link
US (1) US6117949A (es)
AR (1) AR022105A1 (es)
DE (1) DE69937576T2 (es)
PT (1) PT1141079E (es)
ZA (1) ZA200102453B (es)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7087244B2 (en) * 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
US20040228794A1 (en) * 1998-04-10 2004-11-18 Battelle Memorial Institute Therapeutic agent carrier compositions
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
EP1173151B1 (en) 1999-04-16 2003-07-09 Novo Nordisk A/S Dry, mouldable drug formulation
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US7018645B1 (en) * 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6723814B2 (en) * 2000-05-16 2004-04-20 Biocure, Inc. Amphiphilic copolymer planar membranes
EP1315672A4 (en) 2000-06-22 2006-04-26 Rxkinetix Inc ADMINISTRATIVE COMPOSITION COMPOSITION AND METHOD FOR THE ADMINISTRATION OF ANTIGENES AND OTHER ACTIVE SUBSTANCES
DE60127139T2 (de) * 2000-07-14 2007-12-13 Novo Nordisk A/S Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
DK1355566T3 (da) 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
AU2002240755B2 (en) * 2001-03-13 2007-07-05 Angiotech International Ag Micellar drug delivery vehicles and uses thereof
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
JP2004532847A (ja) 2001-04-20 2004-10-28 ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア 疎水性薬物のためのミセル薬物送達システム
KR100488002B1 (ko) * 2001-06-20 2005-05-09 주식회사 삼양사 수용성 폴리알킬렌글리콜로 이루어진 친수성 블록과,방향족 기 함유 α-하이드록시산 유도체와 락타이드의불규칙 공중합체인 소수성 블록으로 이루어진 양친성 블록공중합체
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
KR20030024103A (ko) * 2001-09-17 2003-03-26 육순홍 상전이 현상을 이용한 약물전달용 생분해성 고분자미소구의 제조방법
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7309498B2 (en) * 2001-10-10 2007-12-18 Belenkaya Bronislava G Biodegradable absorbents and methods of preparation
JP2005510521A (ja) * 2001-11-12 2005-04-21 アルカーメス コントロールド セラピューティクス，インコーポレイテッド 生体適合性ポリマーブレンドおよびその使用
WO2003042300A1 (en) * 2001-11-15 2003-05-22 Biomatera Inc. Method for preparing gels
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003080629A2 (en) * 2002-02-25 2003-10-02 Guilford Pharmaceuticals, Inc. Phosphorus-containing compounds with polymeric chains, and methods of making and using the same
US20030228366A1 (en) * 2002-06-11 2003-12-11 Chung Shih Reconstitutable compositions of biodegradable block copolymers
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US20030232088A1 (en) * 2002-06-14 2003-12-18 Kimberly-Clark Worldwide, Inc. Materials with both bioadhesive and biodegradable components
US7037983B2 (en) 2002-06-14 2006-05-02 Kimberly-Clark Worldwide, Inc. Methods of making functional biodegradable polymers
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
MXPA05002561A (es) * 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
MXPA05005038A (es) * 2002-11-12 2005-07-01 Teva Pharma Composiciones farmaceuticas y formas de dosis para la entrega bucal y sublingual de tizanidina y metodos para administrar tizanidina sublingual o bucalmente.
US6992543B2 (en) * 2002-11-22 2006-01-31 Raytheon Company Mems-tuned high power, high efficiency, wide bandwidth power amplifier
MXPA05010068A (es) * 2003-03-21 2005-11-23 Nexmed Holdings Inc Promocion de la angiogenesis por composiciones de prostaglandina y metodos.
AU2004224413A1 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Prostaglandin compositions for the treatment of erectile dysfunction
WO2004103342A2 (en) * 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7179867B2 (en) * 2003-11-26 2007-02-20 Industrial Technology Research Institute Thermosensitive biodegradable copolymer
GB2408510B (en) * 2003-11-28 2008-05-14 Ind Tech Res Inst Thermosensitive biodegradable copolymer
EP1711124A4 (en) * 2004-01-12 2011-06-01 Univ Pennsylvania LONG-TERM RELEASE PREPARATIONS AND METHODS OF USE THEREOF
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
US20050245905A1 (en) * 2004-04-30 2005-11-03 Schmidt Steven P Local drug-delivery system
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060235084A1 (en) * 2005-03-31 2006-10-19 Jorge Heller PEG-polyacetal diblock and triblock copolymers and pharmaceutical compositions
US7456213B2 (en) * 2005-03-31 2008-11-25 A.P. Pharma, Inc. PEG-poly(ortho ester) graft copolymers and pharmaceutical compositions
US20060224095A1 (en) * 2005-04-05 2006-10-05 University Of New Hampshire Biocompatible polymeric vesicles self assembled from triblock copolymers
CA2618807C (en) * 2005-08-12 2015-01-06 University Health Network Methods and devices for lymphatic targeting
US7669732B2 (en) * 2005-10-25 2010-03-02 Imi Cornelius Inc. Cup lid dispenser
JP5401095B2 (ja) 2005-11-17 2014-01-29 ゾゲニクス インコーポレーティッド 無針注射による粘性製剤の送達方法
CN100418528C (zh) * 2006-02-28 2008-09-17 上海华拓医药科技发展有限公司 一种含苦参碱类生物碱的热敏凝胶剂及其制备方法
US7740877B2 (en) 2006-04-07 2010-06-22 University Of Utah Research Foundation Aliphatically modified biodegradable block copolymers as thermogelling polymers
US20100119529A1 (en) * 2006-05-12 2010-05-13 Furgeson Darin Y Elastin-like polymer delivery vehicles
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
AU2007325409B2 (en) * 2006-11-09 2013-03-28 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
US20080140106A1 (en) * 2006-12-12 2008-06-12 Kimberly-Clark Worldwide, Inc. Enhanced cuff sealing for endotracheal tubes
CN100535033C (zh) * 2007-02-13 2009-09-02 四川大学 一种聚乳酸嵌段共聚物及其制备方法
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
TWI388591B (zh) * 2008-03-28 2013-03-11 Ind Tech Res Inst 溫度敏感性材料
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
EP2756756B1 (en) 2008-04-28 2016-01-06 Zogenix, Inc. Novel formulations for treatment of migraine
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
KR101534422B1 (ko) 2008-05-14 2015-07-09 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
US8652506B2 (en) * 2008-06-05 2014-02-18 Boston Scientific Scimed, Inc. Bio-degradable block co-polymers for controlled release
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US20100081622A1 (en) * 2008-09-29 2010-04-01 Sanos Bioscience A/S Reduction of parathyroid hormone levels
TWI374903B (en) 2008-12-31 2012-10-21 Ind Tech Res Inst Biodegradable copolymer hydrogel materials
JP2012526840A (ja) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US20110319987A1 (en) * 2009-05-20 2011-12-29 Arsenal Medical Medical implant
WO2010135433A1 (en) * 2009-05-20 2010-11-25 Arsenal Medical, Inc. Medical implant
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US8753621B2 (en) * 2009-09-18 2014-06-17 Protherics Salt Lake City, Inc. BAB triblock polymers having improved release characteristics
US9155722B2 (en) * 2009-09-18 2015-10-13 Protherics Salt Lake City, Inc. Reconstitutable reverse thermal gelling polymers
KR101838303B1 (ko) * 2009-09-18 2018-03-13 비티지 인터내셔널 리미티드 재구성가능한 가역적 열 겔화 고분자
WO2011035264A1 (en) 2009-09-18 2011-03-24 Protherics Salt Lake City, Inc. Bab triblock polymers having improved release characteristics
WO2011049958A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
GB2480295A (en) * 2010-05-12 2011-11-16 Alan John Waddon Polymeric aqueous composition
CA2719855A1 (en) * 2010-11-02 2012-05-02 University Health Network Temperature sensitive hydrogel and block copolymers
WO2012061907A2 (en) 2010-11-10 2012-05-18 Katholieke Universiteit Leuven Osteoclast activity
KR101966369B1 (ko) 2010-12-17 2019-04-08 에스케이케미칼 주식회사 폴리유산 수지 조성물 및 포장용 필름
KR101286854B1 (ko) * 2011-09-29 2013-07-17 중앙대학교 산학협력단 폴리락트산（ａ）과 폴리에틸렌글리콜（ｂ）로 이루어진 ｂａｂ형 삼중 블록 공중합체, 이의 제조방법 및 이를 이용한 약물전달체
GB201117296D0 (en) * 2011-10-07 2011-11-16 Neotherix Ltd Sampling device
RU2625761C2 (ru) 2012-02-08 2017-07-18 Торэй Индастриз, Инк. Чувствительный к стимулам материал и медицинский материал, содержащий его
RU2508094C1 (ru) * 2012-08-03 2014-02-27 Андрей Юрьевич Хоменко Способы получения трансдермальных терапевтических систем на основе сополимеров молочной и гликолевой кислот (варианты)
US20140271903A1 (en) * 2013-03-14 2014-09-18 Northeast Ohio Medical University Use of thermo-sensitive gel for controlled delivery of alk-5 inhibitors to the eye and related methods
CA2909045C (en) 2013-05-02 2022-12-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
WO2015031393A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
EP2842583A1 (en) 2013-08-29 2015-03-04 Ella-CS, s.r.o. Biodegradable and bioerodible polyurethanes, method of preparation thereof and use thereof
KR20170021353A (ko) 2014-07-03 2017-02-27 오토노미, 인코포레이티드 시프로플록사신 조성물의 멸균
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
SG10201913947RA (en) 2015-06-04 2020-03-30 Crititech Inc Taxane particles and their use
KR20180037994A (ko) 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
WO2017049083A2 (en) 2015-09-16 2017-03-23 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
US11246863B2 (en) 2015-12-11 2022-02-15 Alk-Abelló, Inc. Ciprofloxacin otic composition and kits and method for using same
KR102317108B1 (ko) 2016-04-04 2021-10-25 크리티테크, 인크. 고형 종양의 치료 방법
WO2018053173A1 (en) 2016-09-16 2018-03-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
KR102658256B1 (ko) 2017-03-15 2024-04-16 디에프비 소리아, 엘엘씨 탁산 나노입자를 사용한 피부 악성 종양의 치료용 국소 요법
EP3375452A1 (en) 2017-03-16 2018-09-19 Evangelos Andreakos Use of lambda interferons in the treatment of disorders and related diseases
WO2018175268A1 (en) * 2017-03-19 2018-09-27 Biohealthways, Inc. Biodegrading implantable ocular sustained release drug delivery system
SG10201913649TA (en) 2017-06-09 2020-03-30 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
KR20200060729A (ko) * 2017-10-04 2020-06-01 패션 케미칼즈 게엠베하 운트 코. 카게 신규한 폴리락트산의 에스테르 및 이의 조성물
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
EP3765035A4 (en) 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND ETERNAL CANCER USING TAXANNANO PARTICLES
WO2020254249A1 (en) 2019-06-21 2020-12-24 Proqr Therapeutics Ii B.V. Delivery of nucleic acids for the treatment of auditory disorders
CN114980866A (zh) * 2019-09-09 2022-08-30 帕西拉制药有限公司 包含钠通道阻滞剂的缓释热固性凝胶及其制备方法
CN112354018A (zh) * 2020-11-03 2021-02-12 南京思元医疗技术有限公司 一种用于医疗美容的软组织填充水凝胶及其制备方法
EP4014963A1 (en) * 2020-12-16 2022-06-22 Medincell Pharmaceutical composition
CN113354800A (zh) * 2021-06-22 2021-09-07 山东谷雨春生物科技有限公司 一种peg嵌段聚乙丙交酯及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4438253A (en) * 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
EP0258780B1 (en) * 1986-09-05 1993-06-23 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JPH064540B2 (ja) * 1988-09-14 1994-01-19 多木化学株式会社 医用組成物
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers

Also Published As

Publication number Publication date
ZA200102453B (en) 2001-09-28
DE69937576D1 (de) 2007-12-27
PT1141079E (pt) 2008-02-04
US6117949A (en) 2000-09-12
DE69937576T2 (de) 2008-09-18

Similar Documents

Publication Publication Date Title
AR022105A1 (es) COMPOSICIoN QUE COMPRENDE UN POLíMERO TRIBLOQUE TIPO ABA O TIPO BAB, QUE TIENE PROPIEDADES DE GELACIoN TÉRMICA REVERSIBLE; DICHO POLíMERO TRIBLOQUE; COMPOSICIoN POLIMÉRICA ACUOSA BIODEGRADABLE DE LIBERACIoN DE DROGA QUE LO COMPRENDE Y MÉTODO PARA AUMENTAR LA SOLUBILIDAD DE UNA DROGA MEZCLÁNDOLA EN D
AR015175A1 (es) COMPOSICIoN ACUOSA BIODEGRADABLE POLIMÉRICA PARA LA ENTREGA DE UN FÁRMACO.
ATE378365T1 (de) Bioabbaubare niedermolekulare triblock-polyester- polyethylenglykol-copolymere mit umgekehrter thermischer gelierung
ES2390066T3 (es) Procedimiento para la preparación de micelas poliméricas mediante separación de fase de un copolímero en bloque
Matthew et al. Effect of mammalian cell culture medium on the gelation properties of Pluronic® F127
ES2531679T3 (es) Composiciones para la administración de liberación controlada de péptidos
BRPI0923391B1 (pt) Método de preparo de micelas poliméricas contendo copolímero anfifílico em bloco contendo docetaxel ou paclitaxel
KR20070122521A (ko) Ｐｅｇ-폴리아세탈 및 ｐｅｇ-폴리아세탈-ｐｏｅ 그래프트공중합체 및 약학 조성물
CA2444529A1 (en) Micellar drug delivery systems for hydrophobic drugs
ES2539660T3 (es) Tiras finas de nicotina extrudidas en fundido
KR19990067013A (ko) 폴리(에테르-에스테르) 블록 혼성중합체로 구성된 열감응성생분해가능한 고분자
WO2012126278A1 (zh) 特比萘芬逆向温敏可逆水凝胶组合物
PT1965787E (pt) Tratamento de xerostomia com um antioxidante que contém enxofre
WO1999032151A1 (en) Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
MIYAZAKI et al. Effect of pluronic gels on the rectal absorption of indomethacin in rabbits
US20060235084A1 (en) PEG-polyacetal diblock and triblock copolymers and pharmaceutical compositions
ES2624003T3 (es) Películas de pH modulado para el suministro de principios activos
KR20070122522A (ko) Ｐｅｇ-폴리(오르토 에스테르) 그라프트 공중합체 및 약학조성물
ES2968432T3 (es) Composición farmacéutica
ES2585839T3 (es) Composiciones farmacéuticas tópicas que comprenden aciclovir y ácido hialurónico
KR100214714B1 (ko) 신규한 국소마취제 함유 겔제제
KR102539414B1 (ko) 저분자량의 양친성 블록 공중합체를 포함하는 나노입자의 제조 방법
JP2010229050A (ja) 可溶化組成物
TR2021021176A1 (tr) Ağiz i̇çi̇ enfeksi̇yonlar i̇çi̇n bukkal bi̇yoadezi̇f fi̇lm formülasyonlari
JP2022185721A (ja) 咽喉用組成物

Legal Events

Date Code Title Description
FG Grant, registration